A novel heterozygous point mutation in the p63 gene in a patient with ectodermal dysplasia associated with B-cell leukemia

Pediatric Dermatology

Volumn 28, Issue 6, 2011, Pages 707-710

  Cabanillas, Miguel ^a   Torrelo, Antonio ^b   Monteagudo, Benigno ^a   Suárez Amor, Oscar ^a   Ramírez Santos, Aquilina ^a   González Vilas, Daniel ^a   De Las Heras, Cristina ^a  

^a Universidad de La Coruña   (Spain)

^b HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARAGINASE; BUSULFAN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; PREDNISONE; PROTEIN P63; STEROID; THREONINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANHIDROSIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CHILD; CHILDHOOD LEUKEMIA; CLEFT PALATE; ECTODERMAL DYSPLASIA; HEAT INTOLERANCE; HUMAN; HYPOTRICHOSIS; MALE; MUTATIONAL ANALYSIS; NAIL DISEASE; OLIGODONTIA; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PRURITUS; SCHOOL CHILD; STEROID THERAPY; TRICHORRHEXIS;

ADULT; CHILD; CLEFT LIP; CLEFT PALATE; ECTODERMAL DYSPLASIA; FEMALE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; LEUKEMIA, B-CELL; MALE; POINT MUTATION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 81255152052     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2011.01474.x     Document Type: Article

References (15)

1. Yang A, Schweitzer R, Sun D, et al., p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398: 714-718. (Pubitemid 29197650)
2. Rinne T, Brunner HG, van Bokhoven H,. p63-associated disorders. Cell Cycle 2007; 6: 262-268.
3. Tomkova K, Tomka M, Zajac V,. Contribution of p53, p63, and p73 to the developmental diseases and cancer. Neoplasma 2008; 55: 177-181.
4. Bertola DR, Kim CA, Albano LM, et al., Molecular evidence that AEC syndrome and Rapp-Hodgkin syndrome are variable expression of a single genetic disorder. Clin Genet 2004; 66: 79-80. (Pubitemid 38960826)
5. Steele JA, Hansen H, Arn P, et al., Spectrum of phenotypic manifestations from a single point mutation of the p63 gene, including new cutaneous and immunologic findings. Pediatr Dermatol 2005; 22: 415-419. (Pubitemid 43960994)
6. Rinne T, Hamel B, van Bokhoven H, et al., Pattern of p63 mutations and their phenotypes-update. Am J Med Genet A 2006; 140: 1396-1406. (Pubitemid 43993130)
7. Leõn-Mateos A, Monteagudo B, Rodríguez L, et al., Paciente con manos y pies en "tenaza de langosta": síndrome ectrodactilia-displasia ectodérmica-fisura facial. Actas Dermosifiliogr 2008; 99: 820-830.
8. McGrath JA, Duijf PH, Doetsch V, et al., Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum Mol Genet 2001; 10: 221-229. (Pubitemid 32123980)
9. Luo T, Yu W, Yuan Z, et al., A novel mutation of p63 in a Chinese family with inherited syndactyly and adactylism. Mutat Res 2008; 637: 182-189. (Pubitemid 350256775)
10. Gershoni-Baruch R, Goldscher D, Hochberg Z,. Ectrodactyly-ectodermal dysplasia-clefting syndrome and hypothalamo-pituitary insufficiency. Am J Med Genet 1997; 68: 168-172.
11. Ogutcen-Toller M, Gulen O, Okten G, et al., Non-Hodgkin's lymphoma in a patient with ectrodactyly ectodermal dysplasia-clefting syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90: 124-125.
12. Akahoshi K, Sakazume S, Kosaki K, et al., EEC syndrome type 3 with a hererozygous mutation in the p63 gene and B cell lymphoma. Am J Med Gen 2003; 120: 370-373. (Pubitemid 37063772)
13. Balci S, Engiz O, Okten G, et al., A 19-year follow-up of a patient with type 3 ectrodactyly-ectodermal dysplasia-clefting syndrome who developed non-Hodgkin lymphoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108: 91-95.
14. Moll UM, Slade N,. p63 and p73 roles in development and tumor formation. Mol Cancer Res 2004; 2: 371-386. (Pubitemid 39031071)
15. Di Como CJ, Urist MJ, Babayan I, et al., p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002; 8: 494-501. (Pubitemid 34193969)